1,4-Dihydro-6-methylquinoxaline-2,3-dione is utilized as a key intermediate in pharmaceutical synthesis, especially for developing compounds that modulate glutamate receptors in the central nervous system. It acts as a scaffold for antagonists targeting AMPA and kainate receptors, which play roles in neurotransmission and are linked to disorders such as epilepsy, Alzheimer's disease, and Parkinson's disease. This compound is frequently used in medicinal chemistry research to create bioactive molecules for neuroprotection and signaling studies. Its conjugated structure also enables applications in synthesizing fluorescent probes for biological imaging.